Avid Bioservices Inc (CDMO)

[cjgaddy]

Dr.Hutchins(VP/Preclin-Res.) speaks today at 9amET at the 10th Annual Immunotherapy & Vaccine Summit (ImVacS 2015) in Boston – in session, “Combination Immunotherapy Strategies”…

Aug 24-28 2015: “CHI’s 10th Annual Immunotherapy & Vaccine Summit”, Boston
CHI = Cambridge Healthtech Institute, http://www.healthtech.com
“…This year's event has been expanded to 5 days with coverage on adjuvants, vaccine & immunotherapy technologies, immunomodulatory therapeutic antibodies for cancer, combination cancer immunotherapy, and T cell target discovery. ImVacS 2015 promises to be a must-attend event for commercial and academic entities to continue advancing immunotherapies and vaccines through technology and innovation.”
Event: http://www.imvacs.com/
PGM: Rational Combination Cancer Immunotherapy (1 of 6)
SESSION: COMBINATION IMMUNOTHERAPY STRATEGIES
8-26-15 9-9:30 Jeff T. Hutchins, PhD, VP/Preclin-Res., Peregrine Pharmaceuticals
“Expansion and Activation of T Cells via the Targeting of the Immunosuppressive Ligand Phosphatidylserine (PS): Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”
SUMMARY:
The underlying cause for the failure of current therapies is the persistent and multifocal immune suppression in the tumor microenvironment that drives the absence of pre-existing antitumor T cells. Bavituximab blocks PS-mediated immunosuppression (decreasing MDSCs) by reprograming immune cells in the tumor microenvironment to enhance anticancer activity. Pre-clinical, translational, and clinical results using bavituximab with conventional and immunotherapy combinations promotes a robust, anti-tumor T cell mediated response to enhance cancer therapy.
http://ir.peregrineinc.com/events.cfm